focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Exactly right and it's a lot easier to double the share price from 2p to 4p from this level than from sub 1p etc. i.e. if we are at 2p approx and a positive RNS lands then 4p-5p is very likely. We could then be up to 10p quite quickly based on what we know happened at ARB and that's just for starters....
Good luck, Brighty
Tempest Therapeutics gained 3,973% last month so there is hope for N4P. It's interesting to note that Tempest had a similar share price implosion to N4P's which saw it fall to approx $1 US dollar before results from its liver cancer trial were unveiled. Interestingly their MCAP had collapsed similarly to N4P's at $3 million. It then rose from $3 million to $130 million last month. Come on Nigel, we would like a x39 gain for N4P rather than what you've delivered so far: 30p to 1p is a shocking performance....
Good luck, Brighty
Yes, totally agree about 2p again soon and in the medium term we could be looking at an ARB style rise here, which went from 5p to 250p in a few months (& intra day over 300p+). GST is just getting started....
Good luck, Brighty
Exactly right. As we know Prevail InfoWorks is acting as the Contract Research Organisation (CRO) for the upcoming Phase I clinical trial, which as per the September 18th RNS stated is "expected to commence in 2023".
This will then create the anticipated "value inflection point" for HEMO investors that Prevail's CEO, Mary Schaheen, has mentioned. i.e. Prevail know the true value attached to being a clinical company is a MCAP many multiples of our current share price. e.g. The average licencing deal in our sector in 2023 was $47 Million dollars. Let that sink in....
Good luck, Brighty
Yes, those rises were amazing. See below. Anything is possible......
NCYT 7p to 1210p
ODX 7p to 126p
AVCT 14p – 215p
SNG 6p to 240p
PYC 1.5p to 30p
VAL 6p to 60p
GGP 2p to 35p
ARB 5p to 250p
SAR 0.3p to 9p
UPL 0.5 to 5p
POS 2p to 25p
OBD 10p to 45p
And last month TPST went up x39....
Similar meteoric gains for GST investors could happen here....
Good luck, Brighty
Yes, the appetite for buying GST is currently relentless and we could be back at 2p within the next day or so. The daily fluctuations in the GST share price are almost irrelevant. Jack Bai and his team are building something special here. There's little doubt that this could do an ARB, GGP, UPL, TPST, NCYT, SAR, SNG, POS mega gain....
Good luck, Brighty
Exactly.
* "GST greatly encouraged by the market traction the GS20 Exchange is enjoying".
* "The GS20 Exchange is generating revenue for the Company via trading commissions at varying levels depending on the type and size of transaction undertaken".
That's clearly very good news indeed and what we wanted to hear. We are up and running. Next stop 2p, then 5p and in due course 50p a share.....
Good luck, Brighty
For those of us who invested in NCYT / SNG / GGP / ARB / SAR / POS etc on their amazing rises you'll know that treeshakes just like this happened regularly. You just have to ride them out.....
Good luck, Brighty
Exactly right. Those 5p a share predictions are very modest. This is a huge global market. Don't forget what happened at UPL and POS. They both climbed over x 10 this year on positive sentiment...
Good luck, Brighty
Here is yet another great example of why we are invested in Sareum. When the licencing pay day comes it will be big....
https://www.jpmorgan.com/content/dam/jpm/commercial-banking/insights/life-sciences/jpmorgan-chase-q3-2023-biopharma-final-ada_v2.pdf
Summary and pertinent to SRA 737 and SDC 1801/1802:
* According to JP Morgan's Q3 2023 Biopharma Licensing and Venture Report (just published) there were a total of 113 licensing deals signed in our sector in the third quarter of 2023 ranging from early stage programmes through to P2/3 clinical trials.
* $1.2 billion was paid in total upfront cash and equity in Q3 in licencing deal payments (Q2 1.3 billion)
* For early stage programmes (e.g. 737 and 1801/1802) the average upfront payment was $47 million to date in 2023, up from $40 million in full-year 2022.
In a nutshell, this is more ammo for Stephen Parker to pick up the phone to Professor Kristian Helin, CEO, at the Institute of Cancer Research and Robert James and Ian Miscampbell at Sixth Element / CPF and lobby and persuade them to get a deal over the line for SRA737. It's in everyone's interests....
Good luck, Brighty
Here's some additional data for all HEMO shareholders to get excited about.
* According to JP Morgan's Q3 2023 Biopharma Licensing and Venture Report (just published) there were a total of 113 licensing deals signed in our sector in the third quarter of 2023 ranging from early stage programmes through to P2/3 clinical trials.
* $1.2 billion was paid in total upfront cash and equity in Q3 in licencing deal payments (Q2 1.3 billion)
* In the early stage space Hemo operates in the average upfront payment was $47 million to date in 2023, up from $40 million in full-year 2022. Hopefully, this is where Prevail Partners will be helping HEMO in attracting a similar size licencing deal.
In summary, the significant amounts paid in licencing deals in our sector is another compelling reason to be invested in HEMO.....
Good luck, Brighty
Exactly. The daily fluctuations in the GST share price are almost irrelevant in the bigger scheme of things. Jack Bai, Tone Goh, Shayne Tan and Galvin Bai are building something special here from a very low MCAP. This could seriously rocket very soon and could replicate the ARB, GGP, UPL, TPST, NCYT, SAR, POS mega multi-bagger rises we have all seen over recent years....
Good luck, Brighty
Exactly and we know what happened with ARB. It went from 5p to 250p+ (& over 300p intra-day) in a short few months. Many on here will remember the ARB share price being 20p on Christmas Eve in 2020. Over the Christmas and New Year break it rose in just a few trading sessions to 145p by January 8th 2021....
Good luck, Brighty
Yes, agreed regarding x 10 multibag from here in the short term. Don't forget what happened at UPL and POS. They both climbed over x 10 this year on positive sentiment. 50p a share is where I think this is heading in due course....
Good luck, Brighty
It won't be too long before the UK / FCA will be embracing the NEO bank model. It has to when you bear in mind that NEO banking has a global market size of 72.47 Billion (2022 figures) already. That is a pretty compelling investment strategy. It's why I'm invested in GST as in due course the share price is going to be many times higher than today.
The 5p a share predictions are modest. 50P a share in the medium to long term is not unreasonable, as I've outlined before. This is a huge global market....
Good luck, Brighty
Exactly Barry. Looks like a possible Greatland / Sareum / Argo style leap could be coming here. You only need to see what’s also happened recently at OBD up 300+% in 1 month, POS up 800+% in 1 month, ORCA up 450+% in one month and Tempest up 3900% in October (yes x 39) to get a taster of what could happen here….
Good luck, Brighty